Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2026-01-14 00:00:00 ET · period of report 2026-01-12 · accession 0001140361-26-001239 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-01-14 | 2026-01-12 | ROIV | Venker Eric | Pres, Immunovant CEO | S - Sale+OE | $21.92 | -200.0K | 1.65M | -11% | -$4.38M |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $3.85 | +200.0K | 1.85M | +12% | +$770.0K |
| DT | 2026-01-14 | 2026-01-12 | ROIV | Venker Eric | Pres, Immunovant CEO | M - OptEx | $0.00 | -200.0K | 5.24M | -4% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-01-12 | S | D | 200,000 | $21.92 | 1,654,597 | D | — | — | (F1) The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. |
| 2 | Common | Common Shares | 2026-01-12 | M | A | 200,000 | $3.85 | 1,854,597 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-01-12 | M | D | 200,000 | $0.00 | 5,244,834 | D | $3.85 · — to 2032-04-19 | 200,000 Common Stock | (F2) Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). |